# Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus

> **NCT02238236** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 3793 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial

## Interventions

- **DRUG:** Alesion®

## Key facts

- **NCT ID:** NCT02238236
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 3793 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02238236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02238236, "Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02238236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*